Immunotherapy — targeted drug combination improves survival in advanced kidney cancer
Lenvatinib plus pembrolizumab yields better overall survival than single-agent sunitinib when given as first-line therapy in untreated patients with metastatic kidney cancer The combination also improved progression-free survival and overall response rate BOSTON – Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients…
Details